BioCorRx Announces OTC Markets Transition and Plans Form S-1 Filing to Address Technical Eligibility

BioCorRx Inc. (OTCQB: BICX), a developer of treatment programs for substance abuse and related disorders, announced its common stock will transition from the OTCQB Venture Market to the OTCID Market due to a technical eligibility matter related to OTCQB public float requirements. The company emphasized this transition does not result from any delinquency in its Securities and Exchange Commission reporting obligations, noting it remains current with all periodic reporting and disclosure requirements.

The OTC Markets Group launched the OTCID Market in July 2025 as part of broader structural updates to U.S. over-the-counter equity markets, replacing the former Pink "Current Information" category with a baseline disclosure market for issuers that publish current information and provide management certification. BioCorRx has been a fully reporting public company for approximately 14 years and intends to maintain its established transparency with shareholders.

To address the public float requirement and support eligibility to regain quotation on the OTCQB Venture Market, BioCorRx plans to file a Form S-1 resale registration statement with the SEC. The company clarified it does not expect to raise capital or receive proceeds from this filing, though noted there can be no assurance the registration statement will be declared effective or that the company will regain or maintain OTCQB quotation.

The company does not anticipate changes to business operations or SEC reporting obligations resulting from the quotation tier transition. Shareholders may continue accessing company filings through the SEC's website at https://www.sec.gov, with no interruption expected in reporting or public disclosure availability.

BioCorRx operates through multiple treatment programs and subsidiaries addressing significant public health challenges. The company's Beat Addiction Recovery program combines proprietary Cognitive Behavioral Therapy modules with peer support via mobile app and physician-prescribed medication. Its UnCraveRx Weight Loss Program includes medication-assisted treatment with access to wellness specialists, with more information available at https://www.uncraverx.com.

Through subsidiary BioCorRx Pharmaceuticals Inc., the company focuses on pharmaceutical commercialization and development, including LUCEMYRA (lofexidine), an FDA-approved medication indicated to mitigate opioid withdrawal symptoms in adults. The subsidiary also develops BICX104, an investigational implantable naltrexone pellet program, with research supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number U01DA059994. More information about the company and its pipeline is available at https://www.BioCorRx.com.

The company's work addresses substantial public health needs, including methamphetamine use disorder affecting millions globally and opioid use disorder, a chronic condition with serious consequences including disability and mortality. The World Health Organization reported in 2024 that one in eight people worldwide live with obesity, estimating the global obesity crisis could affect over 4 billion people by 2035 with healthcare costs potentially reaching $4 trillion for related conditions including heart disease, stroke, cancer, and type 2 diabetes.

LUCEMYRA, an oral tablet that reduces norepinephrine release to suppress neurochemical surges producing opioid withdrawal, is indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. Clinical trials demonstrated reduced withdrawal severity compared to placebo. The medication carries important safety considerations, including potential low blood pressure, slow heart rate, and fainting risks, with patients advised to report suspected adverse reactions through appropriate channels including the FDA at https://www.fda.gov/medwatch.

This market transition announcement comes as BioCorRx continues developing treatments for substance use disorders and related conditions affecting significant global populations, while maintaining its commitment to regulatory compliance and shareholder transparency despite technical market eligibility requirements.